TOP TEN perturbations for 39622_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39622_at
Selected probe(set): 206269_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39622_at (206269_at) across 6674 perturbations tested by GENEVESTIGATOR:
tumor supernatant activation study 3 / memory T-cell activation study 1
Relative Expression (log2-ratio):4.506267Number of Samples:4 / 3
| Experimental | tumor supernatant activation study 3 |
| Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:--- | |
| Control | memory T-cell activation study 1 |
| Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs. |
tumor supernatant activation study 3 / untreated memory CD4 T-cell sample
Relative Expression (log2-ratio):4.352758Number of Samples:4 / 3
| Experimental | tumor supernatant activation study 3 |
| Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:--- | |
| Control | untreated memory CD4 T-cell sample |
| Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation. |
asthma study 22 (neutrophilic AIP) / asthma study 22 (paucigranulocytic AIP)
Relative Expression (log2-ratio):3.010684Number of Samples:17 / 10
| Experimental | asthma study 22 (neutrophilic AIP) |
| Sputum samples from asthmatic patients with neutrophilic airway inflammatory phenotype (AIP). | |
| Control | asthma study 22 (paucigranulocytic AIP) |
| Sputum samples from asthmatic patients with paucigranulocytic airway inflammatory phenotype (AIP). |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):-2.7672052Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
asthma study 22 (eosinophilic AIP) / asthma study 22 (neutrophilic AIP)
Relative Expression (log2-ratio):-2.545826Number of Samples:15 / 17
| Experimental | asthma study 22 (eosinophilic AIP) |
| Sputum samples from asthmatic patients with eosinophilic airway inflammatory phenotype (AIP). | |
| Control | asthma study 22 (neutrophilic AIP) |
| Sputum samples from asthmatic patients with neutrophilic airway inflammatory phenotype (AIP). |
acrolein study 2 (2800ug/ml) / vehicle (EtOH) treated bronchial epithelial cell sample
Relative Expression (log2-ratio):2.5223293Number of Samples:3 / 3
| Experimental | acrolein study 2 (2800ug/ml) |
| Bronchial epithelial cells (NHBE) treated with 2800 ug/ml acrolein (within range of concentrations reported to induce toxicity in lung epithelial cells and other cell types) for 8 hours. NHBE cells were derived from a 60 year old male non-smoker. ATC code:--- | |
| Control | vehicle (EtOH) treated bronchial epithelial cell sample |
| Bronchial epithelial cells (NHBE) treated with vehicle (ethanol) at a final concentration of 2% v/v (concentration that ensures >80% cell viability after 24 hours of exposure) for 8 hours. NHBE cells were derived from a 60 year old male non-smoker. |
CVID study 1 (anergic B-cell) / rheumatoid arthritis study 18 (anergic B-cell)
Relative Expression (log2-ratio):2.500928Number of Samples:3 / 2
| Experimental | CVID study 1 (anergic B-cell) |
| Anergic naive B-cells (CD19+,CD10-, CD21-/lo, CD27-) from patients suffering from Common Variable Immunodeficiency Disease (CVID). | |
| Control | rheumatoid arthritis study 18 (anergic B-cell) |
| Anergic naive B-cells (CD19+,CD10-, CD21-/lo, CD27-) from patients suffering from rheumatoid arthritis (RA) affecting multiple (subj.ID:19) or all (subj.ID:1) joints. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):-2.4602652Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal B-cell sample |
| MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
diabetes type 2 study 27 (LCM) / diabetes type 2 study 27 (enzymatic)
Relative Expression (log2-ratio):-2.3394966Number of Samples:34 / 19
| Experimental | diabetes type 2 study 27 (LCM) |
| Pancreatic islet samples obtained from type 2 diabetic (T2D) phenotyped pancreatectomized patients (PPP) and isolated by laser capture microdissection (LCM). Islets specimens were retrieved by LCM from snap-frozen surgical specimen from patients who underwent pancreatectomy for pancreatic diseases. Histopathology of the resected tissue did not reveal insulitis in any PPP. Patients age <18 years were excluded. Patients with type 2 diabetes had fasting glycemia ≥7.0 mmol/l; HbA1C ≥6.5% and history of diabetes for >1 year. | |
| Control | diabetes type 2 study 27 (enzymatic) |
| Pancreatic islet samples obtained from type 2 diabetic (T2D) patients and isolated by enzymatic digestion. Well-preserved islets were isolated by collagenase digestion of pancreas from brain-dead organ donors which suffered from type 2 diabetes. After 2±1 days of culture, islets were successfully hand-picked and processed for further analyses. Type 2 diabetes was diagnosed based on clinical history, treatment with glucose-lowering drugs, and lack of anti-GAD65 autoantibodies. |
smoking study 66 (4h) / normal sham-exposed nasal organotypic tissue
Relative Expression (log2-ratio):2.3391395Number of Samples:3 / 3
| Experimental | smoking study 66 (4h) |
| Human nasal organotypic tissue culture exposed at the air-liquid interface to 16.7% (vol/vol) mainstream cigarette smoke of 4 cigarettes (3R4F, 6-7 minutes each) followed by fresh culture medium incubation for 4 hours. Cigarettes were smoked on a 30-port carousel smoking machine according to health Canada regimen with 1 hour rest between each cigarette. Organotypic culture consisted in a co-culture of primary nasal respiratory epithelial cells derived from a healthy nonsmoking 65-year-old Caucasian male and primary airway fibroblasts derived from a healthy nonsmoking 61-year-old Caucasian male. | |
| Control | normal sham-exposed nasal organotypic tissue |
| Human nasal organotypic tissue culture exposed at the air-liquid interface to 60% humidified air (4 exposure with 1 hour rest between each treatment) followed by fresh culture medium incubation for 4 hours. Organotypic culture consisted in a co-culture of primary nasal respiratory epithelial cells derived from a healthy nonsmoking 65-year-old Caucasian male and primary airway fibroblasts derived from a healthy nonsmoking 61-year-old Caucasian male. |